Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04451408 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3372993 in Participants With Alzheimer's Disease (AD) and Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 139
- Enrollment target
NCT04451408 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 139 participants.
The verdict
NCT04451408, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 139 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the safety and tolerability of LY3372993 in participants with AD, non-Japanese, and Japanese healthy participants who are of first-generation Japanese origin. The study will also investigate how much LY3372993 gets into the bloodstream and will test the effects of LY3372993. The study will be conducted in two parts. The part A includes participants with AD and part B includes healthy participants. Participation could last up to about 61 weeks and may include up to 31 visits to the study center.
Interventions
- DRUG Placebo
- DRUG LY3372993
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 139 participants |
| Start Date | 2020-07-07 |
| Est. Completion | 2024-11-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04451408
The ClinicalTrials.gov registry entry for NCT04451408 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 139 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04451408 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04451408 about?
NCT04451408 is a clinical study titled "A Study of LY3372993 in Participants With Alzheimer's Disease (AD) and Healthy Participants". The main purpose of this study is to evaluate the safety and tolerability of LY3372993 in participants with AD, non-Japanese, and Japanese healthy participants who are of first-generation Japanese origin. The study will also investigate how much LY3372993 gets into the bloodstream and will test the ...
What is the current status of trial NCT04451408?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 139 participants. The study started on 2020-07-07. Estimated completion is 2024-11-18.
What interventions are being tested in trial NCT04451408?
The interventions under investigation include: Placebo (DRUG), LY3372993 (DRUG).
Who is sponsoring clinical trial NCT04451408?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.